Adrian Banks, DO
Family Medicine · Campton, KYNPI 1891089561
Payments from drug & device makers
Across 195 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$585
- GSK$565
- AstraZeneca$368
- Indivior Inc.$292
- Takeda Pharmaceuticals U.S.A., Inc.$235
- Boehringer Ingelheim$221
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,283100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $585 |
| GSK | 33 | $565 |
| AstraZeneca(2 entities) | 17 | $368 |
| Indivior Inc. | 17 | $292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $235 |
| Boehringer Ingelheim | 16 | $221 |
| Pfizer | 10 | $179 |
| Amgen | 8 | $146 |
| Novartis | 8 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $94 |
| Dexcom, Inc. | 3 | $67 |
| Braeburn Inc. | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Antares Pharma, Inc. | 1 | $29 |
| Genentech USA, Inc. | 2 | $26 |
| Electromed, Inc. | 3 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Hologic Inc | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Alkermes, Inc. | 1 | $12 |
How this compares
$3,283 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $99,885 |
| MounjaroTirzepatide | 59 | $60,116 |
| JardianceEmpagliflozin | 50 | $57,577 |
| EliquisApixaban | 36 | $36,396 |
| JanuviaSitagliptin Phosphate | 27 | $33,566 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $22,734 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,601 |
| FarxigaDapagliflozin Propanediol | 17 | $14,002 |
| XareltoRivaroxaban | 17 | $11,498 |
| NeuproRotigotine | 12 | $9,939 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $9,875 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $8,534 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,932 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $5,684 |
| Ventolin HfaAlbuterol Sulfate | 29 | $2,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $33 | $99,88587 claims |
| Lilly USA, LLCMounjaro | $34 | $60,11659 claims |
| Boehringer IngelheimJardiance | $221 | $57,57750 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $368 | $43,66758 claims |
| PfizerEliquis | $179 | $36,39636 claims |
| GSKTrelegy Ellipta | $565 | $14,60122 claims |
| Johnson & JohnsonXarelto | $16 | $11,49817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Campton
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.